219 related articles for article (PubMed ID: 23534533)
21. Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies.
Gao Y; Tan L; Yu JT; Tan L
Curr Alzheimer Res; 2018; 15(3):283-300. PubMed ID: 28413986
[TBL] [Abstract][Full Text] [Related]
22. Tau immunotherapies for Alzheimer's disease.
Hoskin JL; Sabbagh MN; Al-Hasan Y; Decourt B
Expert Opin Investig Drugs; 2019 Jun; 28(6):545-554. PubMed ID: 31094578
[TBL] [Abstract][Full Text] [Related]
23. AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development.
Novak P; Zilka N; Zilkova M; Kovacech B; Skrabana R; Ondrus M; Fialova L; Kontsekova E; Otto M; Novak M
J Prev Alzheimers Dis; 2019; 6(1):63-69. PubMed ID: 30569088
[TBL] [Abstract][Full Text] [Related]
24. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
25. A walk through tau therapeutic strategies.
Jadhav S; Avila J; Schöll M; Kovacs GG; Kövari E; Skrabana R; Evans LD; Kontsekova E; Malawska B; de Silva R; Buee L; Zilka N
Acta Neuropathol Commun; 2019 Feb; 7(1):22. PubMed ID: 30767766
[TBL] [Abstract][Full Text] [Related]
26. Tau immunotherapies: Lessons learned, current status and future considerations.
Sandusky-Beltran LA; Sigurdsson EM
Neuropharmacology; 2020 Sep; 175():108104. PubMed ID: 32360477
[TBL] [Abstract][Full Text] [Related]
27. A Novel Antibody Targeting Tau Phosphorylated at Serine 235 Detects Neurofibrillary Tangles.
Brici D; Götz J; Nisbet RM
J Alzheimers Dis; 2018; 61(3):899-905. PubMed ID: 29332046
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
[TBL] [Abstract][Full Text] [Related]
29. Tau aggregates as immunotherapeutic targets.
Castillo-Carranza DL; Lasagna-Reeves CA; Kayed R
Front Biosci (Schol Ed); 2013 Jan; 5(2):426-38. PubMed ID: 23277060
[TBL] [Abstract][Full Text] [Related]
30. [Significance of tau in the development of Alzheimer's disease].
Takashima A
Brain Nerve; 2010 Jul; 62(7):701-8. PubMed ID: 20675874
[TBL] [Abstract][Full Text] [Related]
31. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
[TBL] [Abstract][Full Text] [Related]
32. Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART.
Kaufman SK; Del Tredici K; Thomas TL; Braak H; Diamond MI
Acta Neuropathol; 2018 Jul; 136(1):57-67. PubMed ID: 29752551
[TBL] [Abstract][Full Text] [Related]
33. Recent developments in tau-based therapeutics for neurodegenerative diseases.
Medina M
Recent Pat CNS Drug Discov; 2011 Jan; 6(1):20-30. PubMed ID: 21118095
[TBL] [Abstract][Full Text] [Related]
34. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
35. Vaccination with Sarkosyl insoluble PHF-tau decrease neurofibrillary tangles formation in aged tau transgenic mouse model: a pilot study.
Ando K; Kabova A; Stygelbout V; Leroy K; Heraud C; Frédérick C; Suain V; Yilmaz Z; Authelet M; Dedecker R; Potier MC; Duyckaerts C; Brion JP
J Alzheimers Dis; 2014; 40 Suppl 1():S135-45. PubMed ID: 24614899
[TBL] [Abstract][Full Text] [Related]
36. Tau immunotherapy and imaging.
Sigurdsson EM
Neurodegener Dis; 2014; 13(2-3):103-6. PubMed ID: 24029727
[TBL] [Abstract][Full Text] [Related]
37. Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.
Combs B; Hamel C; Kanaan NM
Neurobiol Dis; 2016 Oct; 94():18-31. PubMed ID: 27260838
[TBL] [Abstract][Full Text] [Related]
38. Tau immunization: a cautionary tale?
Mably AJ; Kanmert D; Mc Donald JM; Liu W; Caldarone BJ; Lemere CA; O'Nuallain B; Kosik KS; Walsh DM
Neurobiol Aging; 2015 Mar; 36(3):1316-32. PubMed ID: 25619661
[TBL] [Abstract][Full Text] [Related]
39. Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.
West T; Hu Y; Verghese PB; Bateman RJ; Braunstein JB; Fogelman I; Budur K; Florian H; Mendonca N; Holtzman DM
J Prev Alzheimers Dis; 2017; 4(4):236-241. PubMed ID: 29181488
[TBL] [Abstract][Full Text] [Related]
40. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.
Vitale F; Giliberto L; Ruiz S; Steslow K; Marambaud P; d'Abramo C
Acta Neuropathol Commun; 2018 Aug; 6(1):82. PubMed ID: 30134961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
